ArticleCentral-European journal of immunology2025
Pan-cancer analysis of polycomb repressive complex 1 (PRC1) in relation to prognosis and immunotherapy response.
Article in Central-European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Polycomb repressive complex 1 (PRC1) is a crucial epigenetic modification complex that plays significant roles in embryonic development, cell differentiation, and tumorigenesis. However, its predictive value and role in immunotherapy remain unclear. Material and methods: Expression of the PRC1 complex was analyzed through RNA-seq, quantitative PCR, and immunohistochemistry. Then, we utilized the TCGA and GEO databases to cross-validate the prognostic risk. A pan-cancer analysis was conducted, including clinical traits, tumor microenvironment (TME), tumor mutational burden (TMB), stemness indices, and drug sensitivity. Furthermore, we cross-validated the effect of PRC1 on immunotherapy through ROC Plotter and Kaplan-Meier Plotter databases. The immune cell infiltration and signaling pathways were further identified. Results: The expression of PRC1 differed between tumor and normal tissue in most cases. In particular, the whole group exhibited consistent high abundance in gastric, colorectal, and liver cancer. In addition, the expression of PRC1 can serve as a marker of survival prognosis. The members of PRC1 were also associated with clinical characteristics, immune cell infiltration, immune checkpoint inhibitor (ICI)-related immune indexes, and drug sensitivity. Moreover, high expression of BMI1 can increase resistance to immunotherapy, with a worse prognosis. The expression level of BMI1 can affect the immune-related pathways, as indicated by the gene set enrichment analysis (GSEA). Conclusions: Our study revealed the expression, prognostic value and mechanism of PRC1 in pan-cancer. Its core member BMI1 can be used as a biomarker for the prognosis of tumor patients and the efficacy of ICIs. It provides a theoretical basis for the implementation of individualized immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.